1 to 10 of 5,982 literature results

• Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

  Imatinib mesylate (Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia. Here we report ten individuals who developed severe congestiv…

  Authors: Risto Kerkelä, Luanda Grazette, Rinat Yacobi, Cezar Iliescu, Richard Patten, Cara Beahm, Brian Walters, Sergei Shevtsov, Stéphanie Pesant, Fred J Clubb,…

  Source: Nature medicine 2006 Aug

  View Full Text

• Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way.

  Very little is known about how acquired oncogenic mutations arise. In this issue of Cancer Cell, Klemm and colleagues present evidence supporting a role for the antibody diversification enzyme activat…

  Authors: Matthew P Strout, David G Schatz

  Source: Cancer cell 2009 Sep 8

  View Full Text

• Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

  BACKGROUND: Gastrointestinal stromal tumour is the most common sarcoma of the intestinal tract. Imatinib mesylate is a small molecule that inhibits activation of the KIT and platelet-derived growth fa…

  Authors: Ronald P Dematteo, Karla V Ballman, Cristina R Antonescu, Robert G Maki, Peter W T Pisters, George D Demetri, Martin E Blackstein, Charles D Blanke, Margaret von Mehren, Murray F Brennan,…

  Source: Lancet 2009 Mar 28

  View Full Text

• Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder.

  Despite remarkable responses to the tyrosine kinase inhibitor imatinib, CML patients are rarely cured by this therapy perhaps due to imatinib refractoriness of leukemia-initiating cells (LICs). Eviden…

  Authors: Katherine I Oravecz-Wilson, Steven T Philips, Omer H Yilmaz, Heather M Ames, Lina Li, Brendan D Crawford, Alice M Gauvin, Peter C Lucas, Kajal Sitwala, James R Downing,…

  Source: Cancer cell 2009 Aug 4

  View Full Text

• Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications.

  Treatment of chronic myeloid leukemia (CML) with the tyrosine kinase inhibitor imatinib represents a successful application of molecularly targeted cancer therapy. A rapid hematologic and cytogenetic …

  Authors: Ingo Roeder, Matthias Horn, Ingmar Glauche, Andreas Hochhaus, Martin C Mueller, Markus Loeffler

  Source: Nature medicine 2006 Oct

  View Full Text

• Dysregulation of bone remodelling by imatinib mesylate.

  Imatinib mesylate is a rationally designed tyrosine kinase inhibitor that has revolutionised the treatment of chronic myeloid leukaemia and gastro-intestinal stromal tumours. Although the efficacy and…

  Authors: Kate Vandyke, Stephen Fitter, Andrea L Dewar, Timothy P Hughes, Andrew C W Zannettino

  Source: Blood 2009 Nov 4

  View Full Text

• The effects of imatinib on pregnancy outcome.

  Imatinib has now been in use for almost 10 years. Despite this cumulative experience, little is known about its effects on pregnancy; as a result, there are few published data to facilitate the counse…

  Authors: Seonaid M Pye, Jorge Cortes, Patricia Ault, Alan Hatfield, Hagop Kantarjian, Richard Pilot, Gianantonio Rosti, Jane F Apperley

  Source: Blood 2008 Jun 15

  View Full Text

• AMN107: tightening the grip of imatinib.

  The Abl inhibitor imatinib is a highly effective therapy for patients with chronic myeloid leukemia. Relapses are relatively uncommon in newly diagnosed patients, but are the rule in patients with mor…

  Authors: Thomas O'Hare, Denise K Walters, Michael W N Deininger, Brian J Druker

  Source: Cancer cell 2005 Feb

  View Full Text

• SRCircumventing imatinib resistance.

  The ABL inhibitor imatinib is a highly effective therapy for patients with chronic myeloid leukemia. Relapses after an initial response have been observed in some patients, and mutations of the BCR-AB…

  Authors: Michael W N Deininger, Brian J Druker

  Source: Cancer cell 2004 Aug

  View Full Text

• The BCR-ABL story: bench to bedside and back.

  The twenty-first century is beginning with a sharp turn in the field of cancer therapy. Molecular targeted therapies against specific oncogenic events are now possible. The BCR-ABL story represents a …

  Authors: Stephane Wong, Owen N Witte

  Source: Annual review of immunology 2004

  View Full Text